Brentuximab vedotin (ADCETRIS®) targets CD30 using our proprietary antibody–drug conjugate (ADC) technology. CD30 is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma, but not commonly found on healthy cells.
This ADC therapy uses a linker system that is designed to be stable in the bloodstream and release a cytotoxic (cell-killing) agent once internalized into CD30-expressing cells, resulting in targeted cell death. Brentuximab vedotin is composed of an anti-CD30 monoclonal antibody and a cytotoxic agent, monomethyl auristatin E (MMAE), which are attached by a protease-cleavable linker.
Brentuximab vedotin is being developed in collaboration with Takeda Pharmaceutical Company.
Proposed mechanism of action of brentuximab vedotin and nivolumab
This proposed mechanism is based on nonclinical data. Brentuximab vedotin is an investigational agent in this setting. Its safety and efficacy have not yet been established.